FDA Warns Apotex Management To Demand Quality, Meet Specs
Executive Summary
Apotex warning letter reflects FDA’s emphasis on company-wide quality systems and invalidated OOS results.
You may also be interested in...
Some Pointers From The US FDA On How To Conduct Better Out-Of-Spec Investigations
Industry is still having major problems in this area despite the FDA's exhaustive 2006 OOS guidance.
Apotex Withdraws 31 ANDAs After Failing To Ensure Data Integrity At Two Indian Manufacturing Plants
Persistent data integrity and quality unit failures at two Apotex plants in Bangalore, India, led to wholesale US market withdrawals by the Canadian generic drug manufacturer.
The Next New Thing In FDA Inspections: Poor Root Cause Investigations
Data integrity failures are so yesterday. Now it’s all about poor investigations into out-of-specification results.